ADAMTS9-AS2

Across TCGA pan-cancer cohorts, ADAMTS9-AS2 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated ADAMTS9-AS2 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ADAMTS9-AS2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ADAMTS9-AS2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and MESO show a favorable association.

BLCA, KIRC, and LUSC are the cancer types where ADAMTS9-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	II,III,IV	0.333	0.524	<.001	94	view →
KIRC	OS	Median	All	0.716	0.558	<.001	81	view →
LUSC	OS	Quartile	II,III,IV	0.310	0.601	<.001	67	view →
MESO	OS	Tertile	All	0.475	0.205	<.001	61	view →
LUAD	OS	Tertile	All	0.775	0.600	<.001	60	view →
LGG	DFS	Median	All	0.306	0.463	<.001	54	view →
ACC	DFS	Tertile	All	0.206	0.742	<.001	42	view →
UVM	OS	Median	III,IV	0.261	1.000	.001	41	view →
LIHC	OS	Median	III,IV	0.865	0.567	.003	22	view →
STAD	DFS	Tertile	All	0.597	0.803	.029	14	view →
BRCA	OS	Median	III,IV	0.659	0.416	<.001	14	view →
KIRP	DFS	Median	All	0.977	0.800	.007	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

ADAMTS9-AS2–BLCA (OS)

Open the BLCA breakdown →